This Page Intentionally Left Blank - Int Medical

Sickle cell crisis 379
46. Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone
therapy for pain in children and adolescents with sickle cell disease.
N Engl J Med. 1994;330(11):733–737.
47. Couillard S, Benkerrou M, Girot R, et al. Steroid treatment in children with
sickle-cell disease. Haematologica. 2007;92(3):425–426.
48. Weiner DL, Hibberd PL, Betit P, et al. Preliminary assessment of inhaled nitric
oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell
disease. JAMA. 2003;289(9):1136–1142.
49. Steinberg MH. Management of sickle cell disease. N Engl J Med. 1999;340
(13):1021–1030.
50. Ohene-Frempong K. Indications for red cell transfusion in sickle cell disease.
Semin Hematol. 2001;38(1 Suppl 1):5–13.
51. Claster S, Vichinsky EP. Managing sickle cell disease. BMJ. 2003;327
(7424):1151–1155.
52. Davies S, Olujohungbe A. Hydroxyurea for sickle cell disease. Cochrane
Database Syst Rev. 2001(2):CD002202.
53. Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea
in children and young adults with sickle cell disease. Blood. 2001;97
(11):3628–3632.
54. Gibbs WJ, Hagemann TM. Purified poloxamer 188 for sickle cell vaso-occlusive
crisis. Ann Pharmacother. 2004;38(2):320–324.
55. Orringer EP, Casella JF, Ataga KI, et al. Purified poloxamer 188 for treatment of
acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial.
JAMA. 2001;286(17):2099–2106.